Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metastaticcarcinomasubjectscellor equal
  Phrases that lowered it: breast cancertopicalreceptorbloodhormone
• Design: crossover (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Collaborators: 5 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 20.5% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 13585 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Disease area, dermatology: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 89.4% (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients NCT02730130 · started 2016 · scored riskier than 55% of active trials completed
• Trial of Pembrolizumab in Cancer of Unknown Primary NCT03752333 · started 2019 · scored riskier than 90% of active trials completed
• Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer NCT02768701 · started 2016 · scored riskier than 92% of active trials completed
• Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer NCT02316002 · started 2015 · scored riskier than 86% of active trials completed
• Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer NCT02963090 · started 2017 · scored riskier than 84% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.